Grünenthal donates 400.000€ and provides pain treatment medicine to Ukraine
Aachen, Germany, 7 March 2022
Grünenthal, an international science-driven pharmaceutical company, announced that it has donated 400.000€ to the Red Cross to support humanitarian relief efforts in Ukraine and Eastern Europe. In addition, Grünenthal partners with Action Medeor and the University Hospital of RWTH Aachen to provide urgently needed pain medication to the region. The first transport with medicine is set to leave Aachen this week.
“We are shocked and saddened by the attack on Ukraine. Our full solidarity is with Ukraine’s people and everyone affected, no matter where they come from. Grünenthal will contribute to ensuring urgently needed medical care”, said Gabriel Baertschi, CEO of Grünenthal.
Kontakter
Fabia Kehren, Head External Communications & Editorial Management
Tel.: +49 241 569-3269
Fabia.Kehren@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany
Information om Grünenthal Group
Grünenthal GroupAachen, Germany
Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 29 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2020 Grünenthal employed around 4,500 people and achieved sales of € 1.3 bn.
More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
Instagram: grunenthal
Følg pressemeddelelser fra Grünenthal Group
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Grünenthal Group
Maren Thurow starts as new Head Global Communications at Grünenthal20.5.2025 11:05:49 CEST | Press release
Aachen, Germany, 20th May 2025 - Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company’s Communications department since 2021. In her new position, Maren will oversee Grünenthal’s communications operations across all markets and lead the team based at the company’s headquarters in Aachen. She will report directly to CEO Gabriel Baertschi.
Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal24.2.2025 16:19:22 CET | Press release
Aachen, Germany & Toronto, Canada, 24 February 2025 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.
Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer9.1.2025 10:45:57 CET | Press release
Aachen, Germany, 09 January 2025 – Grünenthal announced today that Prof. Dr. Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025.
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain7.11.2024 11:26:47 CET | Press release
The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures per year in the U.S.[2] QUTENZA® is a topical system, non-systemic, non-opioid pain treatment that is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug application (sNDA) for a US label extension in 2026, subject to positive data.
First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist22.10.2024 14:23:50 CEST | Press release
Aachen, Germany, 22 October 2024 – Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound after single and multiple ascending doses. The results of the trial are expected in Q3 2025.